Stress Ulcer Prophylaxis
Published 2008
EAST Practice Management Guidelines Committee
Oscar D. Guillamondegui, MD
Oliver L. Gunter, Jr., MD
John A. Bonadies, MD
Jay E. Coates, DO
Stanley J. Kurek, DO
Marc A. De Moya, MD
Ronald F. Sing, DO
Alan J. Sori MD
Chairman
Oscar D. Guillamondegui, M.D., Vanderbilt University Medical Center, Nashville, Tennessee
oscar.guillamondegui@vanderbilt.edu
Vice-Chair
Oliver L. Gunter Jr., M.D., Washington University, St. Louis, St. Louis, Missouri
guntero@wudosis.wustl.edu
Committee members
John A. Bonadies, M.D., Hospital of Saint Raphael, New Haven, Connecticut
Jay E. Coates, D.O., University of Nevada, Las Vegas, Las Vegas, Nevada
Stanley J. Kurek, D.O., University of Tennessee, Knoxville, Tennessee
Marc A. De Moya, M.D., Massachusetts General Hospital, Boston, Massachusetts
Ronald F. Sing, D.O., Carolinas Medical Center, Charlotte, North Carolina
Alan J. Sori, M.D., St. Joseph Medical Center, Patterson, New Jersey
Statement of the Problem
Stress ulcer prophylaxis has historically been a disease process with a high degree of prevalence in the setting of burns and trauma. Multiple protocols exist for prophylaxis of stress ulcer, but there are no universally accepted regiments. This has led to nationwide disorganization in current practice a stress ulcer prophylaxis. There also remains no universal determination of need for stress ulcer prophylaxis in the trauma population.
The development of clinically significant gastrointestinal hemorrhage has been associated with significant increase of morbidity and mortality. Increase of mortality may be increased as high as 50%.
Process
A MEDLINE search was performed from the years 1990 to present with the following subject words: Gastrointestinal prophylaxis, gastrointestinal hemorrhage, intensive care unit, stress ulcer prophylaxis, trauma, and critical care. All articles pertaining to the critically ill patient were reviewed by 8 trauma intensivists for adequacy and pertinence to the subject.
Quality of the references
The initial literature review identified 119 articles. Of these, 73 were removed secondary to inadequate or inappropriate data. A table of evidence was constructed using the 46 references that were identified. See table 1.[1-46]
The article was entered into a review data sheet that summarized the main conclusions of the study and identified any deficiencies. Reviewers classified each references Class I, Class II or Class III data.
The references were classified using methodology established by the Agency for Health Care Policy and Research (AHCPR) of the U. S. Department of Health and Human Services. Additional criteria and specifications were used for Class I articles from a tool described by Oxman et al.[47]
Articles were categorized as Class I, Class II or Class III data according to the following definitions:
Class I: A prospective randomized clinical trial.
Class II: A prospective non-comparative clinical study or a retrospective analysis based on reliable data.
Class III: A retrospective case series or database review.
The 46 references that met criteria were classified as follows: 27 Class I, 9 Class II, and 10 Class III.
Recommendations from the practice management guideline committee were made on the basis of studies that were included in the evidentiary table. The quality assessment instrument applied to references was that developed by the Brain Trauma Foundation and subsequently adopted by the EAST Practice Management Guidelines Committee.[48] Recommendations were categorized based on the class of data from which they were derived.
Recommendations
What are the risk factors for stress ulcer development and which patients require prophylaxis?
1. Level 1 recommendations
i. Prophylaxis is recommended for all patients with:
- Mechanical ventilation
- Coagulopathy
- Traumatic brain injury
- Major burn injury
2. Level 2 recommendations
i. Prophylaxis is recommended for all ICU patients with:
- Multi-trauma
- Sepsis
- Acute renal failure
3. Level 3 recommendations
i. Prophylaxis is recommended for all ICU patients with:
- ISS>15
- Requirement of high-dose steroids (>250 mg hydrocortisone or equivalent per day)
ii. In selected populations, no prophylaxis is necessary
Is there a preferred agent for stress ulcer prophylaxis? If so, which?
1. Level 1 recommendations
i. There is no difference between H2 antagonists, cytoprotective agents, and some proton pump inhibitors
ii. Antacids should not be used as stress ulcer prophylaxis.
2. Level 2 recommendations
i. Aluminum containing compounds should not be used in patients on dialysis
3. Level 3 recommendations
i. Enteral feeding alone may be insufficient stress ulcer prophylaxis
What is the duration of prophylaxis?
1. Level 1 recommendations
i. There were no level 1 recommendations
2. Level 2 recommendations
i. During mechanical ventilation or intensive care unit stay
3. Level 3 recommendations
i. Until able to tolerate enteral nutrition
Scientific Foundation
Historical
Stress ulcer prophylaxis has been an important part of the care for critical illness for over 20 years. Maynard et al. demonstrated alterations in splanchnic blood flow during acute illness.[49] The physiology of critical illness is frequently complicated with multiple systemic inflammatory abnormalities as well as alterations in hemodynamic status. Systemic hypoperfusion with associated catecholamine search, decreased cardiac output, hypovolemia, vasoconstriction, and inflammatory cytokine release is associated with splanchnic hypoperfusion. In comparison to normal patients, critically ill patients may have disturbances in their mucous and bicarbonate protective layer, owing to alterations in mucosal microcirculation.[26] Overall, the rate of clinically important upper gastrointestinal hemorrhage is low, and is currently rarely seen as a complication of critical illness owing to several potential factors, including strict regimens of prophylaxis. Clinical importance has classically been described as obvious physiologic decline, the requirement of operative for endoscopic intervention, and transfusion requirement. Use of protective agents has historically led to at least a 50% decrease in clinically significant hemorrhage.[50]
Risk Factors
Multiple studies have identified a myriad of risk factors for the development of stress ulceration, although this has not been studied in recent years. Based on the current literature review, the most universally accepted risk factors for stress ulceration are prolonged mechanical ventilation and coagulopathy.[4] [22] [28] [30] [38] Other identified risk factors include multiple injuries, spinal cord injury, injury severity score greater than 15, acute renal failure, and requirement of high-dose steroids.[3] [6] [16] [26] [33] [34]
Timing and duration
If stress ulcer prophylaxis is to be initiated, it should be done so at the onset of risk factors. Based on the current literature review, it is unclear when prophylaxis should be discontinued. Although it has been recommended that prophylaxis be continued for at least 7 days, this has failed to show a difference in outcomes of mortality or GI bleeding.
Most studies recommend the continuation of stress ulcer prophylaxis throughout the duration of critical illness or intensive care unit stay.[29] [38] [41] This strategy would be individualized based on patient physiology.[27] [43]
Medication Choice
There are multiple pharmacologic options for the prophylaxis of stress ulceration.
Histamine-2 receptor antagonists As a measure efficacy, gastric pH should be greater than 4. Tolerance to these medications has been seen, requiring increased dosing based upon gastric pH measurements.[51-53] Several studies have evaluated histamine receptor antagonists in comparison to cytoprotective agents, proton pump inhibitors, placebo, and various routes and dosages of administration with mixed results.
Proton pump inhibitors All studies have shown them to be equivocal to histamine receptor antagonists. Tolerance has not been demonstrated to these medications, however. There currently are no large studies that prove superiority of proton pump inhibitors to histamine receptor antagonists for stress ulcer prophylaxis.[2] [54] Omeprazole suspension has been shown to be effective by any enteral route, and is superior to placebo in the prevention of stress ulceration.[34] [35]
Cytoprotective agents Sucralfate has been the best studied and the most widely used agent in this category. Its use has not been associated with an increase in stress ulceration. Sucralfate has been shown to alter intraluminal pH levels which may affect the portion of further orally administered pharmacologic agents.[24] [46] Numerous studies have shown that the impact on gastric pH is less than that associated with histamine receptor antagonists or proton pump inhibitors which may impact gastric colonization.[4] [5] [8] [9] [14] [22] [27] [38] [43] One study showed increased potential of aluminum toxicity using sucralfate in patients with renal impairment.[55]
Antacids Use of antacids has been associated with a potential increase in the risk of hemorrhage. These agents also have been implicated in an increase in mortality, and are currently not recommended for use.[43]
Enteral feeding Currently, there is limited data supporting the use of enteral nutrition as the sole means of stress ulcer prophylaxis. There is controversy with regard to enteral nutrition administration in the setting of hemodynamic instability requiring pressor agents. Enteral feeding also has failed to show significant increases in gastric pH. There is controversy regarding protective effects of enteral nutrition and whether it is enough to warrant discontinuation of stress ulcer prophylaxis.[8] [19] [46]
No prophylaxis There have been some retrospective studies that have evaluated the need for prophylaxis at all. These studies have been in a mixed ICU population primarily composed of medical patients, as opposed to trauma patients alone.[12] [17] [44] [45] Adequate prospective data is lacking to warrant recommending cessation of prophylaxis.
Summary
All critically ill patients with associated risk factors should receive chemical prophylaxis for stress ulceration. All agents(with the exception of antacids) appear equally adequate for prophylaxis against stress ulceration. The agent of choice should be based upon cost-effective arrangements between vendors and individual hospitals. The duration of treatment is ill-defined, but should be maintained while risk factors are present, the patient is admitted to the intensive care unit, or for a least one week after onset of critical illness. There is currently insufficient evidence to warrant cessation of prophylaxis in the setting of enteral nutrition if other risk factors exist, or to eliminate stress ulcer prophylaxis entirely.
References
- Baghaie AA, Mojtahedzadeh M, Levine RL, et al. Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study. Crit Care Med 1995;23:687-691.
- Balaban DH, Duckworth CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in critically Ill patients. Am J Gastroenterol 1997;92:79-83.
- Ben-Menachem T, Fogel R, Patel RV, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med 1994;121:568-575.
- Bonten MJ, Gaillard CA, van der Geest S, et al. The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double-blind study of sucralfate versus antacids. Am J Respir Crit Care Med 1995;152:1825-1834.
- Bonten MJ, Gaillard CA, van Tiel FH, et al. Continuous enteral feeding counteracts preventive measures for gastric colonization in intensive care unit patients. Crit Care Med 1994;22:939-944.
- Burgess P, Larson GM, Davidson P, et al. Effect of ranitidine on intragastric pH and stress-related upper gastrointestinal bleeding in patients with severe head injury. Dig Dis Sci 1995;40:645-650.
- Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005;33:760-765.
- Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med 1999;27:2812-2817.
- Cook D, Walter S, Freitag A, et al. Adjudicating ventilator-associated pneumonia in a randomized trial of critically ill patients. J Crit Care 1998;13:159-163.
- Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330:377-381.
- Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001;5:368-375.
- Devlin JW, Ben-Menachem T, Ulep SK, et al. Stress ulcer prophylaxis in medical ICU patients: annual utilization in relation to the incidence of endoscopically proven stress ulceration. Ann Pharmacother 1998;32:869-874.
- Eddleston JM, Pearson RC, Holland J, et al. Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo. Crit Care Med 1994;22:1949-1954.
- Eddleston JM, Vohra A, Scott P, et al. A comparison of the frequency of stress ulceration and secondary pneumonia in sucralfate- or ranitidine-treated intensive care unit patients. Crit Care Med 1991;19:1491-1496.
- Ephgrave KS, Kleiman-Wexler R, Pfaller M, et al. Effects of sucralfate vs antacids on gastric pathogens: results of a double-blind clinical trial. Arch Surg 1998;133:251-257.
- Fabian TC, Boucher BA, Croce MA, et al. Pneumonia and stress ulceration in severely injured patients. A prospective evaluation of the effects of stress ulcer prophylaxis. Arch Surg 1993;128:185-191; discussion 191-182.
- Faisy C, Guerot E, Diehl JL, et al. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med 2003;29:1306-1313.
- Geus WP, Vinks AA, Smith SJ, et al. Comparison of two intravenous ranitidine regimens in a homogeneous population of intensive care unit patients. Aliment Pharmacol Ther 1993;7:451-457.
- Gurman G, Samri M, Sarov B, et al. The rate of gastrointestinal bleeding in a general ICU population: a retrospective study. Intensive Care Med 1990;16:4449.
- Hanisch EW, Encke A, Naujoks F, et al. A randomized, double-blind trial for stress ulcer prophylaxis shows no evidence of increased pneumonia. Am J Surg 1998;176:453-457.
- Heiselman DE, Hulisz DT, Fricker R, et al. Randomized comparison of gastric pH control with intermittent and continuous intravenous infusion of famotidine in ICU patients. Am J Gastroenterol 1995;90:277-279.
- Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 2004;51:757-761.
- Kitler ME, Hays A, Enterline JP, et al. Preventing postoperative acute bleeding of the upper part of the gastrointestinal tract. Surg Gynecol Obstet 1990;171:366372.
- Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998;44:527-533.
- Laterre PF, Horsmans Y. Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH. Crit Care Med 2001;29:1931-1935.
- Levy MJ, Seelig CB, Robinson NJ, et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997;42:1255-1259.
- Maier RV, Mitchell D, Gentilello L. Optimal therapy for stress gastritis. Ann Surg 1994;220:353-360; discussion 360-353.
- Martin LF, Booth FV, Karlstadt RG, et al. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993;21:19-30.
- Martin LF, Booth FV, Reines HD, et al. Stress ulcers and organ failure in intubated patients in surgical intensive care units. Ann Surg 1992;215:332-337.
- Metz CA, Livingston DH, Smith JS, et al. Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: a prospective, multicenter, double-blind, randomized trial. The Ranitidine Head Injury Study Group. Crit Care Med 1993;21:1844-1849.
- Mulla H, Peek G, Upton D, et al. Plasma aluminum levels during sucralfate prophylaxis for stress ulceration in critically ill patients on continuous venovenous hemofiltration: a randomized, controlled trial. Crit Care Med 2001;29:267-271.
- Mustafa NA, Akturk G, Ozen I, et al. Acute stress bleeding prophylaxis with sucralfate versus ranitidine and incidence of secondary pneumonia in intensive care unit patients. Intensive Care Med 1995;21:287.
- Pemberton LB, Schaefer N, Goehring L, et al. Oral ranitidine as prophylaxis for gastric stress ulcers in intensive care unit patients: serum concentrations and cost comparisons. Crit Care Med 1993;21:339-342.
- Phillips JO, Metzler MH, Palmieri MT, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-1800.
- Phillips JO, Olsen KM, Rebuck JA, et al. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol 2001;96:367-372.
- Pickworth KK, Falcone RE, Hoogeboom JE, et al. Occurrence of nosocomial pneumonia in mechanically ventilated trauma patients: a comparison of sucralfate and ranitidine. Crit Care Med 1993;21:1856-1862.
- Pimentel M, Roberts DE, Bernstein CN, et al. Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. Am J Gastroenterol 2000;95:2801-2806.
- Prod'hom G, Leuenberger P, Koerfer J, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994;120:653-662.
- Ruiz-Santana S, Ortiz E, Gonzalez B, et al. Stress-induced gastroduodenal lesions and total parenteral nutrition in critically ill patients: frequency, complications, and the value of prophylactic treatment. A prospective, randomized study. Crit Care Med 1991;19:887-891.
- Ryan P, Dawson J, Teres D, et al. Nosocomial pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate. Arch Surg 1993;128:1353-1357.
- Simms HH, DeMaria E, McDonald L, et al. Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective randomized trial. J Trauma 1991;31:531-536; discussion 536-537.
- Simons RK, Hoyt DB, Winchell RJ, et al. A risk analysis of stress ulceration after trauma. J Trauma 1995;39:289-293; discussion 293-284.
- Thomason MH, Payseur ES, Hakenewerth AM, et al. Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine. J Trauma 1996;41:503-508.
- Zandstra DF, Stoutenbeek CP. The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis. A prospective cohort study. Intensive Care Med 1994;20:335-340.
- Zeltsman D, Rowland M, Shanavas Z, et al. Is the incidence of hemorrhagic stress ulceration in surgical critically ill patients affected by modern antacid prophylaxis? Am Surg 1996;62:1010-1013.
- Devlin JW, Claire KS, Dulchavsky SA, et al. Impact of trauma stress ulcer prophylaxis guidelines on drug cost and frequency of major gastrointestinal bleeding. Pharmacotherapy 1999;19:452-460.
- Oxman AD. Checklists for review articles. BMJ 1994;309:648-651.
- Eastern Association for the Surgery of Trauma, EAST Ad Hoc Committee on Practice Management Guideline Development.
- Maynard N, Bihari D, Beale R, et al. Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. JAMA 1993;270:12031210.
- Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996;275:308-314.
- Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994;106:60-64.
- Netzer P, Gut A, Heer R, et al. Five-year audit of ambulatory 24-hour esophageal pH-manometry in clinical practice. Scand J Gastroenterol 1999;34:676-682.
- Wilson P, Clark GW, Anselmino M, et al. Comparison of an intravenous bolus of famotidine and Mylanta II for the control of gastric pH in critically ill patients. Am J Surg 1993;166:621-624; discussion 624-625.
- Mallow S, Rebuck JA, Osler T, et al. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients? Curr Surg 2004;61:452-458.
- Tryba M, Kurz-Muller K, Donner B. Plasma aluminum concentrations in long-term mechanically ventilated patients receiving stress ulcer prophylaxis with sucralfate. Crit Care Med 1994;22:1769-1773.
- Allen ME, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm 2004;61:588-596.
- Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med 2002;30:S373-378.
- Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother 2002;36:1929-1937.
Table
First author | Year | Reference title | Reference |
---|---|---|---|
Baghaie AA |
1995 |
Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective randomized crossover study. |
Crit Care Med.1995 Apr;23(4):68791. |
Study design | Class of data for article | ||
Prospective crossover study on 15 patients comparing gastric pH during continuous and bolus famotidine administration |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Did not address this question |
|
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Continuous infusion is more effective than intermittent dosages in maintaining the "appropriate gastric pH" necessary for SUP |
|||
|
|||
First author | Year | Reference title | Reference |
Balaban DH |
1997 |
Nasogastric omeprazole: effects on gastric pH in critically ill patients. |
Am J Gastroenterol.1997 Jan;92(1):7983. |
Study design | Class of data for article | ||
Prospective, non-randomized on 10 medical ICU patients, looking at effects of omeprazole and ranitidine on gastric pH. |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, omeprazole |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
NGT omeprazole maintained an intragastric pH of > 4.0, and was cost-effective in comparison to ranitidine or famotidine. |
|||
|
|||
First author | Year | Reference title | Reference |
Ben Menachem T |
1994 |
Prophylaxis for stress-related gastric hemorrhage in the MICU |
Ann Intern Med.1994 Oct 15;121(8):56875. |
Study design | Class of data for article | ||
Prospective, randomized, single-blind trial on 300 patients in the MICU comparing placebo, oral sucralfate, or IV infusion of ranitidine. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Respiratory failure, shock, sepsis, cardiac arrest, liver failure, ARF, coagulopathy, pancreatitis, high-dose steroids, anticoagulation |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No difference between cimetidine, sucralfate, and placebo |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? |
|
||
Comments | |||
Medical patients only. Patients with GI bleed 3 RF vs no bleed 2 RF. There was no difference in GI bleed with prophylaxis, but ?underpowered. |
|||
|
|||
First author | Year | Reference title | Reference |
Bonten MJ |
1994 |
Continuous enteral feeding counteracts preventive measures for gastric colonization in ICU patients |
Crit Care Med.1994 Jun;22(6):93944. |
Study design | Class of data for article | ||
Prospective, non-randomized trial eval change in gastric pH with |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question. |
|
||
Comments | |||
Sucralfate with topical ABX was equivalent to STD prophylaxis in prevention of gastric colonization unless pt received enteral feeding. pH was lower in sucralfate group. No mention of GIB outcomes. |
|||
|
|||
First author | Year | Reference title | Reference |
Bonten MJ |
1995 |
The role of intragastric acidity and stress ulcer prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized double-blind study of sucralfate versus antacids. |
Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1825-34. |
Study design | Class of data for article | ||
Single center RCT comparing antacids vs sucralfate, 112 pts, stratified by gastric pH. Outcome measures: VAP, gastric pH, gastric colonization. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Mechanical ventilation |
1 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No difference between sucralfate and antacids |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
VAP rates, mortality rates, and gastric colonization rates were all similar. |
|||
|
|||
First author | Year | Reference title | Reference |
Burgess P |
1995 |
Effect of ranitidine on intragastric pH and stress related upper gastrointestinal bleeding in patients with severe head injury |
Dig Dis Sci. 1995 Mar;40(3):64550. |
Study design | Class of data for article | ||
Single center, RCT,34 patients with traumatic brain injury. Comparison: ranitidine infusion versus placebo. Outcome: GIB, gastric pH. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Severe TBI, mechanical ventilation, renal insufficiency, hepatic insufficiency, hypotension, surgery, multi-trauma. |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, ranitidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? 3 days minimum |
2 |
||
Comments | |||
Small study that showed risk of bleeding significantly increased with decreased gastric pH. Ranitidine effectively increased gastric pH and reduced GIB. |
|||
|
|||
First author | Year | Reference title | Reference |
Conrad SA |
2005 |
Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. |
Crit Care Med.2005 Apr;33(4):7605. |
Study design | Class of data for article | ||
RCT, multi-institutional, 359 pts. Comparison: oral omeprazole vs IV cimetidine. Outcome of GIB and change in gastric pH. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, omeprazole |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question. |
|
||
Comments | |||
Omeprazole (oral) superior to cimetidine (IV) at preventing any overt GIB, noninferior to cimetidine in prevention of clinically significant bleeding. |
|||
|
|||
First author | Year | Reference title | Reference |
Cook D |
1998 |
A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. |
N Engl J Med.1998 Mar 19;338(12):791 7. - |
Study design | Class of data for article | ||
Multicenter RCT 1200 pts. Comparison sucralfate with ranitidine. Outcome: GIB. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, ranitidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question. |
|
||
Comments | |||
Ranitidine superior to sucralfate in prevention of GIB in the ventilated ICU patients. |
|||
|
|||
First author | Year | Reference title | Reference |
Cook D |
1999 |
Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. |
Crit Care Med.1999 Dec;27(12):28 12-7. |
Study design | Class of data for article | ||
Multicenter RCT, 1077 pts. Comparison: ranitidine IV vs sucralfate. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Thrombocytopenia, ARF, MOD, NPO |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Ranitidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Ranitidine superior to sucralfate for GIB prevention. Enteral nutrition is protective. |
|||
|
|||
First author | Year | Reference title | Reference |
Cook DJ |
2001 |
The attributable mortality and length of ICU stay of clinically important gastrointestinal bleeding in critically ill patients. |
Crit Care. 2001 Dec;5(6):36875. Epub 2001 Oct 5. |
Study design | Class of data for article | ||
Retrospective study MICU pts, outcome of ICU LOS and GIB |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Mechanical ventilation |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Did not address this question |
|
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
GIB increases mortality and ICU length of stay. Recommended selective prophylaxis. |
|||
|
|||
First author | Year | Reference title | Reference |
Cook DJ |
1994 |
Risk factors for gastrointestinal bleeding in critically ill patients. |
N Engl J Med.1994 Feb 10;330(6):37781. |
Study design | Class of data for article | ||
Retrospective study, single center, 2252 pts. Comparison: GIB vs no GIB. |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Respiratory failure, shock, sepsis, cardiac arrest, liver failure, ARF, coagulopathy, pancreatitis, high-dose steroids, organ transplantation, anticoagulation |
3 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Did not address this question |
|
||
What is the appropriate duration for stress ulcer prophylaxis in this population? When risk factors are no longer present |
2 |
||
Comments | |||
Most important risk factors or mechanical ventilation greater than 48 hours and coagulopathy. Prophylaxis decreases bleeding risk by 50%. |
|||
|
|||
First author | Year | Reference title | Reference |
Devlin JW |
1998 |
Stress ulcer prophylaxis in MICU patients: annual utilization in relation to the incidence of endoscopically proven stress ulceration. |
Ann Pharmacother.1998 Sep;32(9):86974. |
Study design | Class of data for article | ||
Retrospective study of MICU patients, single institution. Outcome of endoscopic GI stress ulceration. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No prophylaxis is necessary |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
MICU study showing that selective prophylaxis does not increase endoscopic GIB |
|||
|
|||
First author | Year | Reference title | Reference |
Devlin JW |
1999 |
Impact of trauma stress ulcer prophylaxis guidelines on drug cost and frequency of major gastrointestinal bleeding |
Pharmacother apy.1999 Apr;19(4):45260. |
Study design | Class of data for article | ||
single center, retrospective, non-randomized, 300 patients. Comparison: Outcome: Cost, GIB. Pharmacy study. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? TBI, SCI, coagulopathy, mech vent, postop with NGT, PUD last 6 mos, gastric tonometry, MD preference |
3 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, cimetidine |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Discontinue after pt. tolerating a diet or enteral feeding. Gave cimetidine. Saved $5000 in 150 patients, and had no GI bleeding complications. |
|||
|
|||
First author | Year | Reference title | Reference |
Eddleston J |
1991 |
A comparison of frequency of stress ulceration and secondary pneumonia in sucralfate-or ranitidine-treated intensive care unit patients |
Crit Care Med.1991 Dec;19(12):14 91-6. |
Study design | Class of data for article | ||
Single center RCT, 60 patients. Comparison: sucralfate versus ranitidine. Outcome: stress ulceration, VAP, gastric pH. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? SICU pts with mech vent and high risk for stress ulceration |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, sucralfate |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Gastric pH, colonization, and VAP increased with ranitidine, sucralfate recommended. bleeding complications. |
|||
|
|||
First author | Year | Reference title | Reference |
Eddleston JM |
1994 |
Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo. |
Crit Care Med.1994 Dec;22(12):19 49-54. |
Study design | Class of data for article | ||
Prospective RCT, single institution. 26 pts, sucralfate vs placebo. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Sucralfate |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Small study showing decrease endoscopic pathology with sucralfate. |
|||
|
|||
First author | Year | Reference title | Reference |
Ephgrave KS |
1998 |
Effects of sucralfate versus antacids on gastric pathogens: results of a double-blind clinical trial. |
Arch Surg. 1998 Mar;133(3):251 7. |
Study design | Class of data for article | ||
Single center RCT comparing sucralfate vs antacids of 140 VA patients undergoing major surgery requiring NGT. Outcomes: gastric pH, pneumonia, GIB. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No difference between sucralfate and antacids |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
No difference in pneumonia or GIB between the study groups. Increased gastric colonization in antacids vs sucralfate, unclear significance. |
|||
|
|||
First author | Year | Reference title | Reference |
Fabian, TC |
1993 |
Pneumonia and stress ulceration in severely injured patients. A prospective evaluation of the effects of stress ulcer prophylaxis |
Arch Surg. 1993 Feb;128(2):18 5-91; discussion 191 2. |
Study design | Class of data for article | ||
Single center RCT, 278 trauma patients. Comparison: sucralfate, bolus cimetidine, infusion cimetidine. Outcome: Stress ulceration, pneumonia. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Spinal cord injury |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No difference between cimetidine and sucralfate |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Discontinued with discharge or death, minimum of 3 days. |
2 |
||
Comments | |||
No difference in VAP rates |
|||
|
|||
First author | Year | Reference title | Reference |
Faisy C |
2003 |
Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. |
Intensive Care Med. 2003 Aug;29(8):130 6-13. Epub 2003 Jun 26. |
Study design | Class of data for article | ||
Single-center retrospective study, 1473 pts. Comparison: prophylaxis vs no prophylaxis. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Mechanical ventilation greater than 48 hours, coagulopathy and acute renal failure |
3 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No prophylaxis is necessary |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
No difference in GIB with and without prophylaxis. Recommended further study. |
|||
|
|||
First author | Year | Reference title | Reference |
Geus WP |
1993 |
Comparison of two IV ranitidine regimens in a homogenous population of ICU patients. |
Aliment Pharmacol Ther. 1993 Aug;7(4):4517. |
Study design | Class of data for article | ||
Single center RCT comparing infusion vs bolus ranitidine, 18 pts. Outcome measures: gastric pH |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, ranitidine |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
No difference between infusion vs bolus ranitidine. |
|||
|
|||
First author | Year | Reference title | Reference |
Gurman G |
1990 |
The rate of gastrointestinal bleeding in a general ICU population: a retrospective study. |
Intensive Care Med.1990;16(1):449. |
Study design | Class of data for article | ||
Retrospective study 298 patients. Comparison b/w antacids, cimetidine, both, and enteral nutrition. Outcome: coffee-ground emesis or melena. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Antacids +/- cimetidine |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Continued until able to tolerate enteral nutrition |
3 |
||
Comments | |||
Stopped treatment with enteral feeding, no real data significance between antacid/H2 blocker patients, enteral feeding had increased hemorrhage |
|||
|
|||
First author | Year | Reference title | Reference |
Hansich EW |
1998 |
A randomized, double-blind trial for stress ulcer prophylaxis shows no evidence of increased pneumonia. |
Am J Surg. 1998 Nov;176(5):45 3-7. |
Study design | Class of data for article | ||
Single center, RCT, 158 patients. Comparison: placebo, ranitidine, pirenzepine. Outcome: VAP. |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? SICU and mechanically ventilated |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
No difference between ranitidine and pirenzepine with regard to VAP. Placebo group had low incidence of GIB, ?powered to study this effect. |
|||
|
|||
First author | Year | Reference title | Reference |
Heiselman DE |
1995 |
Randomized comparison of gastric pH control with intermittent and continuous intravenous infusion of famotidine in ICU patients. |
Am J Gastroenterol.1995 Feb;90(2):2779. |
Study design | Class of data for article | ||
Singe center RCT, 40 patients. Comparison: continuous vs bolus famotidine. Outcome: gastric pH. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Famotidine bolus followed by infusion |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
No statistical difference in GI bleed, and hospital mortality. pH increased most in bolus followed by infusion. |
|||
|
|||
First author | Year | Reference title | Reference |
Kantorova I |
2004 |
Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. |
Hepatogastroe nterology. 2004 MayJun;51(57):757 61. |
Study design | Class of data for article | ||
Single center RCT, 287 patients. Comparison: omeprazole, famotidine, sucralfate, placebo. Outcome: GIB, pneumonia, gastric pH. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Coagulopathy |
1 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
No difference between any treatment arm and GIB, pneumonia. Increased gastric pH may increase pneumonia rate. |
|||
|
|||
First author | Year | Reference title | Reference |
Kitler ME |
1990 |
Preventing postoperative acute bleeding of the upper part of the gastrointestinal tract |
Surg Gynecol Obstet. 1990 Nov;171(5):36 6-72. |
Study design | Class of data for article | ||
Prospective randomized trial, 298 pts in the ICU comparing bioflavonoid, sucralfate, and Maalox. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Critically ill patients in the ICU, age >50 yrs. |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
No difference in the bleeding based on the various treatments. Age >50 correlated to bleeding. Small study. |
|||
|
|||
First author | Year | Reference title | Reference |
Lasky MR |
1998 |
A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients |
J Trauma. 1998 Mar;44(3):52733. |
Study design | Class of data for article | ||
Single center, retrospective study, 60 pts. Comparison: None. Outcome: GIB, gastric pH, pneumonia. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, omeprazole |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Omeprazole suspension is safe and effective as prophylaxis. Gastric pH is appropriately elevated. Omeprazole suspension is cost-effective. |
|||
|
|||
First author | Year | Reference title | Reference |
Laterre PF |
2001 |
Intravenous omeprazole in critically ill patients: a crossover study comparing 40 with 80 mg plus 8 mg/hr on intragastric pH. |
Crit Care Med.2001 Oct;29(10):193 1-5. |
Study design | Class of data for article | ||
Single center prospective crossover trial, 10 pts. Comparison 40mg bolus omeprazole vs 80mg +8mg/hr gtt. Outcome: gastric pH. |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, omeprazole 40 mg bolus /day |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
40 mg PPI as good as higher doses and continuous infusion for gastric pH. |
|||
|
|||
First author | Year | Reference title | Reference |
Levy MJ |
1997 |
Comparison of omeprazole and ranitidine for stress ulcer prophylaxis |
Dig Dis Sci. 1997 Jun;42(6):1255 9. |
Study design | Class of data for article | ||
Prospective RCT, single institution, 67 pts. Comparison: ranitidine, omeprazole. Outcome: pneumonia, GIB. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Coagulopathy, burn, severe trauma, respiratory failure, coagulopathic, TBI, acute renal failure, sepsis |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, omeprazole |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Higher number of GIB in the ranitidine group in comparison to omeprazole, 11 vs 2. ?Underpowered secondary to low incidence. Unclear RE: risk factors. Duration not addressed. |
|||
|
|||
First author | Year | Reference title | Reference |
Maier RV |
1994 |
Optimal therapy for stress gastritis |
Ann Surg. 1994 Sep;220(3):35 3-60; discussion 360 3. |
Study design | Class of data for article | ||
Single center RCT in 98 trauma patients. Comparison: ranitidine +antacids vs sucralfate. Outcome: VAP, GIB, LOS, cost. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No difference between sucralfate and ranitidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
H2 blockers increase gastric pH more effectively, but no clinical difference in GIB episodes. pH and colonization may be responsible for pneumonia. |
|||
|
|||
First author | Year | Reference title | Reference |
Martin LF |
1993 |
Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. |
Crit Care Med. 1993 Jan;21(1):1930. |
Study design | Class of data for article | ||
Multicenter RCT comparing IV cimetidine to placebo, 117 patients. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Major surgery, burns >30% TBSA, respiratory failure, multi-trauma, hypotensive, hypovolemic shock, metabolic acidosis, sepsis |
1 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, cimetidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Good multicenter, double-blinded, placebo controlled study to compare continuous IV cimetidine to nothing. pH increases with H2 blockers, but not associated with increased rate of GIB |
|||
|
|||
First author | Year | Reference title | Reference |
Martin LF |
1992 |
Stress ulcers and organ failure in intubated patients in SICUs. |
Ann Surg. 1992 Apr;215(4):332 7. |
Study design | Class of data for article | ||
Multicenter RCT, 127 SICU patients. Comparison: PO misoprostol and IV placebo vs PO placebo and IV cimetidine. Outcome: GIB, |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Mechanical ventilation in patients with hypotension or sepsis |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No difference between misoprostol and cimetidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? 14 days or ICU discharge |
2 |
||
Comments | |||
Aggressive endoscopic surveillance in very ill SICU population. Prophylaxis may not eliminate mucosal lesions, but does decrease surgically significant bleeding. |
|||
|
|||
First author | Year | Reference title | Reference |
Metz CA |
1993 |
Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: a prospective, multicenter, double-blind randomized trial. |
Crit Care Med.1993 Dec;21(12):18 44-9. |
Study design | Class of data for article | ||
Prospective, multicenter, RCT, ten ICUs. Comparison: infusion ranitidine vs placebo. Outcome GIB. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Head injury, mechanical ventilation, serum cr>20, SGOT or SGPT > twice normal, PLT<75K, PT>nl, SBP<90, major operation, other clinically important trauma (blunt chest/long bone fx), GCS<6, ASA use |
1 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, ranitidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Good multicenter, double-blinded, placebo controlled study. Complications increased with 2 or more risk factors. Unclear definitions for UGIB. |
|||
|
|||
First author | Year | Reference title | Reference |
Mulla H |
2001 |
Plasma aluminum levels during sucralfate prophylaxis for stress ulceration in critically ill patients on continuous venovenous hemofiltration: a randomized, controlled trial. |
Crit Care Med.2001 Feb;29(2):26771. |
Study design | Class of data for article | ||
Single center RCT, 20 patients. Comparison: sucralfate versus IV ranitidine. Outcome: plasma aluminum samples. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Should not use sucralfate in patients requiring CVVH |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Should not use sucralfate in patients undergoing CVVH |
|||
|
|||
First author | Year | Reference title | Reference |
Mustafa NA |
1995 |
Acute stress bleeding prophylaxis with sucralfate versus ranitidine and incidence of secondary pneumonia in ICU patients. |
Intensive Care Med. 1995 Mar;21(3):287. |
Study design | Class of data for article | ||
Single center RCT, 31 patients. Comparison: sucralfate versus ranitidine. Outcome: stress ulcer bleeding, pneumonia. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? no, sucralfate equivalent to ranitidine |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Small study, sucralfate comparable to ranitidine. Ranitidine increases gastric pH which may increase tracheobronchial colonization. |
|||
|
|||
First author | Year | Reference title | Reference |
Pemberton LB |
1993 |
Oral ranitidine as prophylaxis for gastric stress ulcers in intensive care unit patients: serum concentrations and cost comparisons. |
Crit Care Med. 1993 Mar;21(3):33942. |
Study design | Class of data for article | ||
Single center prospective non-randomized trial, 18 patients. Comparison: ranitidine 150 mg versus 300 mg. Outcome: serum ranitidine concentrations. |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Sepsis, mech vent, major trauma, hypotension (<90mmHg) |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, oral ranitidine |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Only looked at ranitidine, oral administration ok and lower dose (150mg)as effective as higher dose (300mg), given twice daily. |
|||
|
|||
First author | Year | Reference title | Reference |
Phillips JO |
1996 |
A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. |
Crit Care Med.1996 Nov;24(11):17 93-800. |
Study design | Class of data for article | ||
Prospective, unrandomized, single center study, mixed SICU population outcome with omeprazole suspension. |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? -SICU patients with anticipated 48 hr stay and any one of the following: TBI, burns, ARF, acid base d/o, multitrauma, coagulopathy, multiple operations, coma, hypotension >1hr, sepsis |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, omeprazole |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Shows efficacy and safety of PPI, no placebo group. Significant increase in pH. |
|||
|
|||
First author | Year | Reference title | Reference |
Phillips JO |
2001 |
A randomized, pharmacokinetic and pharmacodynamic, crossover study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. |
Am J Gastroenterol.2001 Feb;96(2):36772. |
Study design | Class of data for article | ||
Randomized crossover study, 9 surgical patients. Comparison: gastric vs enteral route. Outcome: intragastric pH. |
2 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Mechanical ventilation |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Did not address this question |
|
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Small study only 9 patients gastric vs enteral omeprazole. Efficacy is similar for either route. |
|||
|
|||
First author | Year | Reference title | Reference |
Pickworth KK |
1993 |
Occurrence of nosocomial pneumonia in mechanically ventilated trauma patients: a comparison of sucralfate and ranitidine |
Crit Care Med.1993 Dec;21(12):18 56-62. |
Study design | Class of data for article | ||
Single center RCT, 83 patients. Comparison sucralfate versus ranitidine. Outcomes: pneumonia. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No difference between sucralfate and ranitidine |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? 3 days minimum |
3 |
||
Comments | |||
Small study found no difference between sucralfate and ranitidine RE: pneumonia. |
|||
|
|||
First author | Year | Reference title | Reference |
Pimentel M |
2000 |
Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. |
Am J Gastroenterol.2000 Oct;95(10):280 1-6. |
Study design | Class of data for article | ||
Retrospective review of 7200 patients, identifying 12 with bleeding. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Age, septic shock, AAA repair, and enteral or parenteral nutrition |
3 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Risk factors were identified in 12 patients that developed GIB. Did not support SUP. |
|||
|
|||
First author | Year | Reference title | Reference |
Prod'hom G |
1994 |
Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A RCT. |
Ann Intern Med.1994 Apr 15;120(8):65362. |
Study design | Class of data for article | ||
Single center non-placebo controlled RCT, 244 ICU pts. Comparison: antacids, ranitidine, sucralfate. Outcome: GIB, gastric pH, pneumonia |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Mechanical ventilation |
1 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Yes, sucralfate |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? until extubated or out of the ICU |
2 |
||
Comments | |||
SUP prophylaxis with sucralfate reduces the risk for late onset pneumonia in vented patients, with similar protection compared to antacids and ranitidine. |
|||
|
|||
First author | Year | Reference title | Reference |
Ruiz-Santana S |
1991 |
Stress-induced gastroduodenal lesions and total parenteral nutrition in critically ill patients: frequency, complications and value of prophylactic treatment |
Crit Care Med.1991 Jul;19(7):88791. |
Study design | Class of data for article | ||
Single center RCT 97 pts on TPN. Comparison: TPN, TPN+sucralfate, TPN+ranitidine. Outcome: GIB. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Mechanical ventilation >6 days |
2 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Small study, no difference in GIB while on TPN with or without prophylaxis. |
|||
|
|||
First author | Year | Reference title | Reference |
Ryan P |
1993 |
Nosocomial Pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate |
Arch Surg. 1993 Dec;128(12):1 353-7. |
Study design | Class of data for article | ||
Single center, RCT, 114 pts. Comparison: Cimetidine infusion versus sucralfate. Outcome:GIB, VAP. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No difference between sucralfate and cimetidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Nice study with decent number of pts, 56 and 58 in each arm but focused on Nosocomial pneumonia and did not define UGI bleed. |
|||
|
|||
First author | Year | Reference title | Reference |
Simms H |
1991 |
Role of gastric colonization in the development of pneumonia in critically ill patients |
J Trauma. 1991 Apr;31(4):5316; discussion 536-7. |
Study design | Class of data for article | ||
single center RCT, 89 pts. Comparison: antacids vs cimetidine vs sucralfate. Outcome: Gastric pH, pneumonia. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No |
2 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? ICU stay |
2 |
||
Comments | |||
Small trial, main outcome was pneumonia, no difference between groups |
|||
|
|||
First author | Year | Reference title | Reference |
Simons RK |
1995 |
A risk analysis of stress ulceration after trauma |
J Trauma. 1995 Aug;39(2):28993; discussion 293-4. |
Study design | Class of data for article | ||
Retrospective review of trauma patients identifying risk factors, low incidence. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? ISS >=16, RTS<13, AIS head >=3, SCI |
3 |
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? Did not address this question. |
|
||
What is the appropriate duration for stress ulcer prophylaxis in this population? When risk factors are no longer present, unless SCI then 3 weeks |
3 |
||
Comments | |||
Overall rate of stress ulcer hemorrhage is low, with or without prophylaxis, the SCI population should continue for 3 wks |
|||
|
|||
First author | Year | Reference title | Reference |
Thomason MH |
1996 |
Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid and ranitidine |
J Trauma. 1996 Sep;41(3):5038. |
Study design | Class of data for article | ||
Single center, RCT, 242 pts. Comparison: Sucralfate, antacid, ranitidine. Outcome: Mortality, GIB, pneumonia. |
1 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No, sucralfate equivalent to ranitidine |
1 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
Antacids associated with higher mortality compared to sucralfate and ranitidine which had equivalent GIB and pneumonia rates. |
|||
|
|||
First author | Year | Reference title | Reference |
Zandstra DF |
1994 |
The virtual absence of stress-ulcer related bleeding in ICU patients receiving prolonged mechanical ventilation. A prospective cohort study. |
Intensive Care Med. 1994 May;20(5):33540. |
Study design | Class of data for article | ||
Retrospective study, 183 mixed ICU patients. Comparison: None. Outcome: GIB. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No prophylaxis is necessary |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? Did not address this question |
|
||
Comments | |||
No prophylaxis given, 1% incidence of GIB. Patients were considered high-risk with mean Tryba risk score of 38. All patients received cefotaxime, steroids, and DVT prophylaxis. |
|||
|
|||
First author | Year | Reference title | Reference |
Zeltsman D |
1996 |
Is the incidence of hemorrhagic stress ulceration in surgically critically ill patients affected by modern antacid prophylaxis? |
Am Surg. 1996 Dec;62(12):10 10-3. |
Study design | Class of data for article | ||
Single center retrospective study, 304 pts. Comparison:H2 blockers +/- antacids vs no prophylaxis. Outcome: Hemorrhagic stress ulceration. |
3 |
||
Questions | Class of data for question | ||
What are the risk factors for stress ulcer development and which trauma patients require prophylaxis? Did not address this question |
|
||
Is there a preferred agent for stress ulcer prophylaxis? If so, what? No prophylaxis is necessary |
3 |
||
What is the appropriate duration for stress ulcer prophylaxis in this population? ICU stay |
3 |
||
Comments | |||
Multidisciplinary ICU with no difference in hemorrhage with or without H2 blockade, does not distinguish if trauma patients had differential stress ulcer hemorrhage. |